Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemay808 Phase 2 in mild-to-moderate atopic dermatitis
NCT04352595Phase 2Completed
- Sponsor
- Tianjin Hemay Biotech
- Start
- Apr 2020
- Primary completion
- Feb 2021
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hemay808 in atopic dermatitis (AD), sponsored by Tianjin Hemay Biotech. Started Apr 2020; status: completed.
02
Drugs
hemay808
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04352595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04352595.